- |||||||||| Clinical, Review, Journal: Lp(a): A Rapidly Evolving Therapeutic Landscape. (Pubmed Central) - Nov 22, 2024
While there are presently no Lp(a)-lowering drugs available for routine clinical use, several promising candidates are currently under investigation. If these prove to be effective in randomized clinical trials, they will expand the cardiovascular care armamentarium and will allow clinicians to treat a presently unmitigated cardiovascular risk factor.
- |||||||||| Review, Journal: RNA interference therapy in cardiology: will new targets improve therapeutic goals? (Pubmed Central) - Aug 27, 2024
Zilebesiran, which targets hepatic angiotensinogen mRNA, has demonstrated a dose-related reduction in serum angiotensinogen levels, thereby lowering blood pressure in patients with systemic arterial hypertension...In the future, larger studies will provide insights into improvements in cardiovascular outcomes, long-term safety and broader applications in the general population. This review highlights the historical timeline of the development of siRNA-based drugs, their clinical indications, potential side-effects and future perspectives.
- |||||||||| olpasiran (AMG 890) / Amgen, pelacarsen (AKCEA-APO(a)-LRx) / Ionis, Novartis, lepodisiran (LY3819469) / Eli Lilly
Review, Journal: New insights into the therapeutic options to lower lipoprotein(a). (Pubmed Central) - Aug 23, 2024
This review highlights the historical timeline of the development of siRNA-based drugs, their clinical indications, potential side-effects and future perspectives. If the results from the cardiovascular outcome trials, designed to demonstrate whether the reduction of Lp(a) of more than 80% as observed with pelacarsen, olpasiran or lepodisiran translates into the decrease of cardiovascular mortality and major adverse cardiovascular events, will be positive, lowering Lp(a) will become a new additional target in the management of patients with elevated cardiovascular risk.
- |||||||||| lepodisiran (LY3819469) / Eli Lilly
Journal: Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease. (Pubmed Central) - Jul 14, 2024
If the results from the cardiovascular outcome trials, designed to demonstrate whether the reduction of Lp(a) of more than 80% as observed with pelacarsen, olpasiran or lepodisiran translates into the decrease of cardiovascular mortality and major adverse cardiovascular events, will be positive, lowering Lp(a) will become a new additional target in the management of patients with elevated cardiovascular risk. No abstract available
- |||||||||| Journal: Therapeutic Potential of Lipoprotein(a) Inhibitors. (Pubmed Central) - Jun 8, 2024
These agents are moving forward in clinical development, in order to determine whether Lp(a) lowering reduces cardiovascular risk. The results of these studies have the potential to transform our approach to the prevention of cardiovascular disease.
- |||||||||| The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels, Elevated Lp(a) And Inflammation: What Are The Best Medical Strategies To Decrease These Parameters: Statins, Adjunctive LDL-C Lowering Drugs Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen, Etc.) And Anti-Inflammatories: How They Should Be Administered (Grand Ballroom West, 3rd Floor) - May 28, 2024 - Abstract #VEITH2024VEITH_416;
- |||||||||| lepodisiran (LY3819469) / Eli Lilly
Journal: Lepodisiran for Elevated Lipoprotein(a). (Pubmed Central) - Apr 23, 2024
The results of these studies have the potential to transform our approach to the prevention of cardiovascular disease. No abstract available
- |||||||||| muvalaplin (LY3473329) / Eli Lilly, lepodisiran (LY3819469) / Eli Lilly
Review, Journal: Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand? (Pubmed Central) - Apr 1, 2024
In particular, we discuss novel agents, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that are currently being developed and target Lp(a). The promising role of muvalaplin, an oral inhibitor of Lp(a) formation, is then further analyzed.
- |||||||||| Review, Journal: Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. (Pubmed Central) - Mar 5, 2024
Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.
- |||||||||| Review, Journal: Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? (Pubmed Central) - Feb 21, 2024
Promising treatment approaches targeting apo(a) expression include RNA-based drugs such as pelacarsen, olpasiran, SLN360, and lepodisiran, which are currently in clinical trials. In this comprehensive review, we provide a detailed overview of RNA-based therapeutic approaches and discuss the recent advances and challenges of RNA therapeutics specifically designed to reduce Lp(a) levels and thus the risk of cardiovascular disease.
- |||||||||| Review, Journal: Molecular Therapies in Cardiovascular Diseases: Small Interfering RNA in Atherosclerosis, Heart Failure, and Hypertension. (Pubmed Central) - Jan 15, 2024
Zilebesiran, designed to reduce angiotensinogen secretion, significantly decreases systolic and diastolic blood pressure (BP). Thanks to their effectiveness, safety, and tolerability profile, and with a very low number of administrations in a year, thus overcoming adherence issues, these novel drugs are the leaders of a new era in molecular therapies for CV diseases.
- |||||||||| lepodisiran (LY3819469) / Eli Lilly
Trial completion: A Study to Compare Two Formulations of LY3819469 in Healthy Participants (clinicaltrials.gov) - Jan 5, 2024
P1, N=27, Completed,
Thanks to their effectiveness, safety, and tolerability profile, and with a very low number of administrations in a year, thus overcoming adherence issues, these novel drugs are the leaders of a new era in molecular therapies for CV diseases. Active, not recruiting --> Completed
- |||||||||| Review, Journal: Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a). (Pubmed Central) - Sep 13, 2023
Traditional pharmacological interventions like niacin, statins, ezetimibe, aspirin, PCSK-9 inhibitors, mipomersen, estrogens and CETP inhibitors have not yet yielded satisfactory results...Pelacarsen is an antisense oligonucleotide, while olpasiran, LY3819469 and SLN360 are small interfering RNAs, all conjugated with a N-acetylgalactosamine molecule...The Lp(a) reduction achieved with novel RNA agents may exceed 95%. The results of ongoing and future clinical trials are eagerly anticipated, and it is hoped that guidelines for the tailored management of Lp(a) levels with these novel agents may not be far off.
- |||||||||| lepodisiran (LY3819469) / Eli Lilly
Enrollment open: A Study to Compare Two Formulations of LY3819469 in Healthy Participants (clinicaltrials.gov) - Aug 1, 2023
P1, N=28, Recruiting,
The results of ongoing and future clinical trials are eagerly anticipated, and it is hoped that guidelines for the tailored management of Lp(a) levels with these novel agents may not be far off. Not yet recruiting --> Recruiting
- |||||||||| Review, Journal: Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. (Pubmed Central) - Dec 24, 2022
Hence, drugs based on RNA technology, such as pelacarsen, olpasiran, SLN360 and LY3819469, are undergoing clinical trials. These drugs are very effective in lowering the serum Lp(a) concentration and have a satisfactory safety profile, which means that in the near future they will fill an important gap in the armamentarium of lipid-lowering drugs.
- |||||||||| lepodisiran (LY3819469) / Eli Lilly
Trial completion: A Study of LY3819469 in Healthy Participants (clinicaltrials.gov) - Nov 21, 2022
P1, N=66, Completed,
These drugs are very effective in lowering the serum Lp(a) concentration and have a satisfactory safety profile, which means that in the near future they will fill an important gap in the armamentarium of lipid-lowering drugs. Active, not recruiting --> Completed
- |||||||||| lepodisiran (LY3819469) / Eli Lilly
Enrollment closed: A Study of LY3819469 in Healthy Participants (clinicaltrials.gov) - Mar 23, 2022
P1, N=66, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| lepodisiran (LY3819469) / Eli Lilly
Enrollment open: A Study of LY3819469 in Healthy Participants (clinicaltrials.gov) - Jul 6, 2021
P1, N=66, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
|
